Definition

An individualized peptide-based cancer vaccine comprised of three to five human leukocyte antigen (HLA) binding tumor-specific peptides obtained from the autologous mutated proteins from the tumor cells of patients with acute lymphoblastic leukemia (ALL), with potential immunomodulating and antineoplastic activity. Upon intradermal administration of the personalized multi-HLA-binding peptide vaccine, the peptides may induce a tumor-specific cytotoxic T-lymphocyte (CTL) response against the peptides that are expressed by the tumor cells.